Courtney D. DiNardo, MD, MSCE


Unmet Needs of AML and Advice for Community Oncologists

Courtney DiNardo, MD, concludes with discussing some challenges faced when treating patients with AML and shares some advice for community oncologists treating acute myeloid leukemia.

Rachel Wuerstein, MD


Next Steps for Trastuzumab Emtansine After the KAMILLA Trial

Rachel Würstlein, MD, discusses the use of trastuzumab emtansine following the KAMILLA trial which evaluated the agent in patients with HER2-positive locally advanced or metastatic breast cancer who have brain metastases.

Cristian Tomasetti, PhD


Using ctDNA in Stage II Colon Cancer

Cristian Tomasetti, discusses the role of circulating tumor-DNA after surgery in patients with stage II colon cancer.

Jerome H. Goldschmidt, MD


EP. 9A: The Rationale for CDK4/6 Inhibition in ES-SCLC and Updates on Trilaciclib Clinical Trial Data

In the fifth interview of the series, medical oncologist and hematologist Dr. Jerome H. Goldschmidt from Blue Ridge Cancer Care elaborates on the rationale for use of CDK4/6 inhibitors such as trilaciclib for prevention of chemotherapy-induced myelosuppression (CIM) in extensive-stage small cell lung cancer (ES-SCLC), and touches on recently presented data on trilaciclib.

Gilles Salles, MD, PhD


How Will New Immunotherapies Fit Into the Treatment Landscape of Follicular Lymphoma?

Future directions for follicular lymphoma treatments include potential use earlier in treatment or as combination therapy, identifying patients who will benefit most from treatment, and minimizing the costs of therapy while maximizing accessibility.

David M. Waterhouse, MD, MPH


Expert Highlights Immunotherapy Advances in Lung Cancer Treatment Landscape

David M. Waterhouse, MD, MPH, shares advice with community oncologists treating patients with lung cancer.

Hagop M. Kantarjian


Kantarjian on Solutions for Oncology Drug Shortages

According to Hagop M. Kantarjian, MD, there are options for limited oncology drug shortages that require multi-sector involvement.

Hayley Virgil


Maintenance Niraparib Dose Modification Does Not Affect PFS in Ovarian Cancer

Among patients with newly diagnosed, advanced ovarian cancer, dose modifications to frontline niraparib maintenance therapy did not affect progression-free survival.

Suresh S. Ramalingam, MD


FLAURA Trial Demonstrates Efficacy in EGFR-Positive Lung Cancer

Suresh S. Ramalingam, MD, discusses the phase III FLAURA trial.

Katherine E. Poruk, MD


Melanoma Monday: A Review of the MSLT-II Trial and Completion Lymph Node Dissection

Katherine E. Poruk, MD, reviews the use of complete axillary lymph node dissection and the Multicenter Selective Lymphadenectomy Trial II for Melanoma Monday.

Andrei Gafita, MD


Investigating Prognostic Markers for OS With LuPSMA Treatment in mCRPC

Andrei Gafita, MD, discusses the overall survival in patients with metastatic castration-resistant prostate cancer who received 177Lutetium-prostate-specific membrane antigen radionuclide treatment.

Darlene Dobkowski, MA


Biomarkers May Predict Outcomes With Specific Antibody Drug Conjugate for Urothelial Carcinoma Treatment

Tumor mutation burden was linked with improved survival while some alterations were linked with inferior outcomes from treatment with enfortumab vedotin for urothelial carcinoma.

Marin F. Xavier, MD


Next Steps Using Anti-CD19 Therapies in DLBCL

The future of combined treatment approaches with anti-CD19 therapies for diffuse large B-cell lymphoma.

Andrew G. Gianoukakis, MD


Multikinase Inhibitor Options Flourish for Patients With RET-Mutant Medullary Thyroid Cancer

During a Targeted Oncology Case-Based Peer Perspectives event, Andrew G. Gianoukakis, MD, FACE, discussed the use of multikinase inhibitors for RET-mutated medullary thyroid cancer.

Melissa M. Hardesty, MD


Further Research Needed to Improve Outcomes in Advanced Ovarian Cancer

Melissa M. Hardesty discusses the key takeaways of the phase 2 OVARIO study of a PARP inhibitor plus a VEGF inhibitor in women with advanced ovarian cancer as well as research still needs to examine in this space.

Rupesh Kotecha, MD


Kotecha Analyzes Use of 45 Gy Novel Radiotherapy in CNS Cancers

Rupesh Kotecha, MD, discusses results of an analysis which centered around the use of pulse reduced dose rate intensity-modulated radiotherapy in patients with central nervous system malignancies.

David I. Quinn, MD, PhD, MBBS


Roundtable Discussion: Addressing Management of Patients with Metastatic CRPC Following Frontline Treatments

During a Targeted Oncology Case-Based Roundtable event, David I. Quinn, MD, PhD, MBBS leads a discussion on treatment for metastatic castration-resistant prostate cancer following frontline treatment.

Parvez Mantry, MD


Future Treatment Approaches for HCC

Closing out their discussion on the management of hepatocellular carcinoma, panelists discuss future novel therapies that may impact the treatment landscape.

Srikanth Nagalla, MD, MS


Hematology Workforce Shortage Poses Challenges for Cancer Care

Srikanth Nagalla, MD, MS, describes initiatives to improve the talent pipeline for hematology staff at all levels.

Ashley Hay, BSN, RN


Immune Checkpoint to Watch: ICOS

Developing modern strategies to predict and accurately monitor treatment response remains an important piece of the clinical management puzzle.

Kushal Naha, MD


Mitigating Toxicities Arising From Combination Therapies in RCC

Combination therapy with checkpoint blockade, also termed immuno oncology agents, and multikinase tyrosine kinase inhibitors are rapidly becoming the first-line therapy of choice in patients with metastatic clear cell renal cell carcinoma.

Usama Gergis, MD


Gergis Explains the Differences Between Acute and Chronic GVHD

Usama Gergis, MD, MBA, reviewed that difference in acute and chronic graft-versus-host disease and the treatment available for each

Charles L. Sawyers, MD


The Importance of IMspire150 Data Is Questioned in Melanoma Treatment Landscape

Charles L. Sawyers, MD, discusses the value of atezolizumab, cobimetinib, and vemurafenib in the melanoma treatment landscape.

Elizabeth Wulff-Burchfield, MD


Managing TKI-Related Adverse Events in RCC

An overview of adverse event and toxicity considerations with TKI therapies in renal cell carcinoma.

Daniel Landau, MD


PARP Inhibition in Metastatic CRPC: The PROfound and TRITON2 Studies

Expert perspectives on the PROfound and TRITON2 studies of olaparib and rucaparib, respectively, in metastatic castration-resistant prostate cancer.

Jaffer A. Ajani, MD


CheckMate 649 Study in GI Cancers Shows Survival Benefit for Nivolumab/Chemotherapy

Jaffer A. Ajani, MD, discusses the design and results of the CheckMate 649 study of nivolumab, ipilimumab, and chemotherapy for gastric cancers.

Shuichi Hironaka, MD, PhD


Phase I/II Study Demonstrates Good Efficacy for Gastric Cancer

Shuichi Hironaka, MD, PhD, discusses the efficacy of a phase I/II study of nivolumab, paclitaxel, and ramucirumab as second-line treatment of patients with advanced gastric cancer during the 2020 Gastrointestinal Cancers Symposium.

Lewis R. Roberts, PhD, MB, ChB


Achieving Health Equity in Liver Cancer

Primary liver cancer death rates vary by region, and much is still to be done in the area of health equity.